Cargando…
Clinical utility of chitotriosidase enzyme activity in nephropathic cystinosis
BACKGROUND: Nephropathic cystinosis is an inherited autosomal recessive lysosomal storage disorder characterized by the pathological accumulation and crystallization of cystine inside different cell types. WBC cystine determination forms the basis for the diagnosis and therapeutic monitoring with th...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269071/ https://www.ncbi.nlm.nih.gov/pubmed/25407738 http://dx.doi.org/10.1186/s13023-014-0155-z |
_version_ | 1782349315903062016 |
---|---|
author | Elmonem, Mohamed A Makar, Samuel H van den Heuvel, Lambertus Abdelaziz, Hanan Abdelrahman, Safaa M Bossuyt, Xavier Janssen, Mirian C Cornelissen, Elisabeth AM Lefeber, Dirk J Joosten, Leo AB Nabhan, Marwa M Arcolino, Fanny O Hassan, Fayza A Gaide Chevronnay, Héloïse P Soliman, Neveen A Levtchenko, Elena |
author_facet | Elmonem, Mohamed A Makar, Samuel H van den Heuvel, Lambertus Abdelaziz, Hanan Abdelrahman, Safaa M Bossuyt, Xavier Janssen, Mirian C Cornelissen, Elisabeth AM Lefeber, Dirk J Joosten, Leo AB Nabhan, Marwa M Arcolino, Fanny O Hassan, Fayza A Gaide Chevronnay, Héloïse P Soliman, Neveen A Levtchenko, Elena |
author_sort | Elmonem, Mohamed A |
collection | PubMed |
description | BACKGROUND: Nephropathic cystinosis is an inherited autosomal recessive lysosomal storage disorder characterized by the pathological accumulation and crystallization of cystine inside different cell types. WBC cystine determination forms the basis for the diagnosis and therapeutic monitoring with the cystine depleting drug (cysteamine). The chitotriosidase enzyme is a human chitinase, produced by activated macrophages. Its elevation is documented in several lysosomal storage disorders. Although, about 6% of Caucasians have enzyme deficiency due to homozygosity of 24-bp duplication mutation in the chitotriosidase gene, it is currently established as a screening marker and therapeutic monitor for Gaucher’s disease. METHODS: Plasma chitotriosidase activity was measured in 45 cystinotic patients, and compared with 87 healthy controls and 54 renal disease patients with different degrees of renal failure (CKD1-5). Chitotriosidase levels were also correlated with WBC cystine in 32 treated patients. Furthermore, we incubated control human macrophages in-vitro with different concentrations of cystine crystals and monitored the response of tumor necrosis factor-alpha (TNF-α) and chitotriosidase activity. We also compared plasma chitotriosidase activity in cystinotic knocked-out (n = 10) versus wild-type mice (n = 10). RESULTS: Plasma chitotriosidase activity in cystinotic patients (0–3880, median 163 nmol/ml/h) was significantly elevated compared to healthy controls (0–90, median 18 nmol/ml/h) and to CKD patients (0–321, median 52 nmol/ml/h), P < 0.001 for both groups. Controls with decreased renal function had mild to moderate chitotriosidase elevations; however, their levels were significantly lower than in cystinotic patients with comparable degree of renal insufficiency. Chitotriosidase activity positively correlated with WBC cystine content for patients on cysteamine therapy (r = 0.8), P < 0.001. In culture, human control macrophages engulfed cystine crystals and released TNF-α into culture supernatant in a crystal concentration dependent manner. Chitotriosidase activity was also significantly increased in macrophage supernatant and cell-lysate. Furthermore, chitotriosidase activity was significantly higher in cystinotic knocked-out than in the wild-type mice, P = 0.003. CONCLUSIONS: This study indicates that cystine crystals are potent activators of human macrophages and that chitotriosidase activity is a useful marker for this activation and a promising clinical biomarker and therapeutic monitor for nephropathic cystinosis. |
format | Online Article Text |
id | pubmed-4269071 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42690712014-12-18 Clinical utility of chitotriosidase enzyme activity in nephropathic cystinosis Elmonem, Mohamed A Makar, Samuel H van den Heuvel, Lambertus Abdelaziz, Hanan Abdelrahman, Safaa M Bossuyt, Xavier Janssen, Mirian C Cornelissen, Elisabeth AM Lefeber, Dirk J Joosten, Leo AB Nabhan, Marwa M Arcolino, Fanny O Hassan, Fayza A Gaide Chevronnay, Héloïse P Soliman, Neveen A Levtchenko, Elena Orphanet J Rare Dis Research BACKGROUND: Nephropathic cystinosis is an inherited autosomal recessive lysosomal storage disorder characterized by the pathological accumulation and crystallization of cystine inside different cell types. WBC cystine determination forms the basis for the diagnosis and therapeutic monitoring with the cystine depleting drug (cysteamine). The chitotriosidase enzyme is a human chitinase, produced by activated macrophages. Its elevation is documented in several lysosomal storage disorders. Although, about 6% of Caucasians have enzyme deficiency due to homozygosity of 24-bp duplication mutation in the chitotriosidase gene, it is currently established as a screening marker and therapeutic monitor for Gaucher’s disease. METHODS: Plasma chitotriosidase activity was measured in 45 cystinotic patients, and compared with 87 healthy controls and 54 renal disease patients with different degrees of renal failure (CKD1-5). Chitotriosidase levels were also correlated with WBC cystine in 32 treated patients. Furthermore, we incubated control human macrophages in-vitro with different concentrations of cystine crystals and monitored the response of tumor necrosis factor-alpha (TNF-α) and chitotriosidase activity. We also compared plasma chitotriosidase activity in cystinotic knocked-out (n = 10) versus wild-type mice (n = 10). RESULTS: Plasma chitotriosidase activity in cystinotic patients (0–3880, median 163 nmol/ml/h) was significantly elevated compared to healthy controls (0–90, median 18 nmol/ml/h) and to CKD patients (0–321, median 52 nmol/ml/h), P < 0.001 for both groups. Controls with decreased renal function had mild to moderate chitotriosidase elevations; however, their levels were significantly lower than in cystinotic patients with comparable degree of renal insufficiency. Chitotriosidase activity positively correlated with WBC cystine content for patients on cysteamine therapy (r = 0.8), P < 0.001. In culture, human control macrophages engulfed cystine crystals and released TNF-α into culture supernatant in a crystal concentration dependent manner. Chitotriosidase activity was also significantly increased in macrophage supernatant and cell-lysate. Furthermore, chitotriosidase activity was significantly higher in cystinotic knocked-out than in the wild-type mice, P = 0.003. CONCLUSIONS: This study indicates that cystine crystals are potent activators of human macrophages and that chitotriosidase activity is a useful marker for this activation and a promising clinical biomarker and therapeutic monitor for nephropathic cystinosis. BioMed Central 2014-11-19 /pmc/articles/PMC4269071/ /pubmed/25407738 http://dx.doi.org/10.1186/s13023-014-0155-z Text en © Elmonem et al.; licensee BioMed Central Ltd. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Elmonem, Mohamed A Makar, Samuel H van den Heuvel, Lambertus Abdelaziz, Hanan Abdelrahman, Safaa M Bossuyt, Xavier Janssen, Mirian C Cornelissen, Elisabeth AM Lefeber, Dirk J Joosten, Leo AB Nabhan, Marwa M Arcolino, Fanny O Hassan, Fayza A Gaide Chevronnay, Héloïse P Soliman, Neveen A Levtchenko, Elena Clinical utility of chitotriosidase enzyme activity in nephropathic cystinosis |
title | Clinical utility of chitotriosidase enzyme activity in nephropathic cystinosis |
title_full | Clinical utility of chitotriosidase enzyme activity in nephropathic cystinosis |
title_fullStr | Clinical utility of chitotriosidase enzyme activity in nephropathic cystinosis |
title_full_unstemmed | Clinical utility of chitotriosidase enzyme activity in nephropathic cystinosis |
title_short | Clinical utility of chitotriosidase enzyme activity in nephropathic cystinosis |
title_sort | clinical utility of chitotriosidase enzyme activity in nephropathic cystinosis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269071/ https://www.ncbi.nlm.nih.gov/pubmed/25407738 http://dx.doi.org/10.1186/s13023-014-0155-z |
work_keys_str_mv | AT elmonemmohameda clinicalutilityofchitotriosidaseenzymeactivityinnephropathiccystinosis AT makarsamuelh clinicalutilityofchitotriosidaseenzymeactivityinnephropathiccystinosis AT vandenheuvellambertus clinicalutilityofchitotriosidaseenzymeactivityinnephropathiccystinosis AT abdelazizhanan clinicalutilityofchitotriosidaseenzymeactivityinnephropathiccystinosis AT abdelrahmansafaam clinicalutilityofchitotriosidaseenzymeactivityinnephropathiccystinosis AT bossuytxavier clinicalutilityofchitotriosidaseenzymeactivityinnephropathiccystinosis AT janssenmirianc clinicalutilityofchitotriosidaseenzymeactivityinnephropathiccystinosis AT cornelissenelisabetham clinicalutilityofchitotriosidaseenzymeactivityinnephropathiccystinosis AT lefeberdirkj clinicalutilityofchitotriosidaseenzymeactivityinnephropathiccystinosis AT joostenleoab clinicalutilityofchitotriosidaseenzymeactivityinnephropathiccystinosis AT nabhanmarwam clinicalutilityofchitotriosidaseenzymeactivityinnephropathiccystinosis AT arcolinofannyo clinicalutilityofchitotriosidaseenzymeactivityinnephropathiccystinosis AT hassanfayzaa clinicalutilityofchitotriosidaseenzymeactivityinnephropathiccystinosis AT gaidechevronnayheloisep clinicalutilityofchitotriosidaseenzymeactivityinnephropathiccystinosis AT solimanneveena clinicalutilityofchitotriosidaseenzymeactivityinnephropathiccystinosis AT levtchenkoelena clinicalutilityofchitotriosidaseenzymeactivityinnephropathiccystinosis |